Prescription medicine
Camizestrant Brand names: Etcamah
Camizestrant (Etcamah) is a prescription medicine with an FDA approval on record since 2026. No generic is listed in FDA's NDC Directory.
- No generic listed
- Boxed warning
Check it at the source: the camizestrant FDA label on DailyMed (effective September 4, 2026, AstraZeneca Pharmaceuticals LP); the NDA 220359 record on Drugs@FDA; every camizestrant label on DailyMed.
Highlights of the record
FDA label of September 4, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
ARRHYTHMIA RISK WITH CONCOMITANT USE OF.
QTc INTERVAL PROLONGING DRUGS ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death ( 5.1 , 5.2 , 7.1 ). Avoid concomitant use of ETCAMAH with products (other than ribociclib) known to prolong the QTc interval and/or have a known risk of Torsades de Pointes. If concomitant use with other products cannot be avoided, monitor the QTc interval more frequently ( 5.1 , 7.3 ). Obtain ECG prior to initiation and monitor heart rate and QTc interval during treatment. Assess and correct electrolyte abnormalities prior to initiation and during treatment. Withhold ETCAMAH until resolution of QTc interval prolongation and resume or permanently discontinue ETCAMAH based on severity. ( 2.2 , 2.4 ) WARNING: ARRHYTHMIA RISK WITH CONCOMITANT USE OF QTc INTERVAL PROLONGING DRUGS See full prescribing information for complete boxed warning.
ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death ( 5.1 , 5.2 , 7.1 ). […]
Used for
From the label: indications and usageETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test [see Dosage and Admin
Forms and strengths
- 75 mg
Film-coated tablet.
On the market
- Earliest approval on file
- September 4, 2026 Etcamah, Astrazeneca; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 13 through July 30, 2026
What is camizestrant used for?
From the label: indications and usageETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test [see Dosage and Administration ( 2.1 )]. This indication is approved under accelerated approval based on progression-free survival as measured from detection of ESR1 mutation [see Clinical Studies ( 14 )]. […]
Source: FDA drug label (ETCAMAH), AstraZeneca Pharmaceuticals LP, effective September 4, 2026 (SPL set c54223d3-f3c7-4186-afa0-429d84805826), via openFDA; the full label on DailyMed
Is there a generic for camizestrant (Etcamah)?
No generic camizestrant is approved (Drugs@FDA, October 8, 2026).
- 2026 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the camizestrant label say about other medicines?
The camizestrant label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Abemaciclib | drug interactions | If concomitant use with a moderate CYP3A inducer cannot be avoided, dose adjustment is needed when ETCAMAH is given in combination with abemaciclib or palbociclib. |
| Palbociclib | drug interactions | If concomitant use with a moderate CYP3A inducer cannot be avoided, dose adjustment is needed when ETCAMAH is given in combination with abemaciclib or palbociclib. |
| Ribociclib | boxed warning | ARRHYTHMIA RISK WITH CONCOMITANT USE OF QTc INTERVAL PROLONGING DRUGS ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden … |
Source: FDA drug label (ETCAMAH), AstraZeneca Pharmaceuticals LP, effective September 4, 2026 (SPL set c54223d3-f3c7-4186-afa0-429d84805826), via openFDA; the full label on DailyMed
What do FAERS reports show for camizestrant?
The FDA Adverse Event Reporting System holds 13 reports that list camizestrant among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1 are coded as a death and 12 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Camizestrant side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other